Printer Friendly

This Complete 3 Volume Set of the Handbook of Tuberculosis Examines in Detail this Infection and its Vaccination Process.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of "Handbook of Tuberculosis, 3 Volume Set" to their offering.

Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes' lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease.

Dr. Stefan Kaufmann, the Founding Director of the Max Planck Institute for Infection Biology in Berlin and Professor of Microbiology and Immunology at the Charite at the Humboldt University, Berlin, has published more than 600 scientific articles and currently serves as President of the European Federation of Immunological Societies and Chair of the Immunology Division of the American Society of Microbiology. Dr. Kaufmann is considered the world's leading expert in the field of tuberculosis.

The Handbook of Tuberculosis, which explores the causes and available treatments of the widespread infection as well as current research into vaccination, is divided into three separate volumes covering different areas of study.

Volume 1: Molecular Biology and Biochemistry highlights the molecular mechanisms of tuberculosis. The book is co-edited by Dr. Eric Rubin, Professor of Immunology and Infectious Diseases at the Harvard School of Public Health. It provides the basis for the three-volume set by focusing on the genomic and genetic nature of the pathogen as well as current medical advancements that combat the bacterium on a molecular level.

Volume 2: Immunology and Cell Biology is co-edited by Dr. Warwick Britton, Professor of Medicine at the University of Sydney and head of the Mycobacterial Research Program at the Centenary Institute, Sydney, Australia. It presents the pre-eminent resource for all aspects of cell biology and immunology of tuberculosis, including vaccine development.

Volume 3: Clinics, Diagnostics, Therapy and Epidemiology introduces a comprehensive overview of clinical aspects of tuberculosis, including drug resistance, epidemiological aspects and clinical trials. It is co-edited by Dr. Paul van Helden, Professor of Medical Biochemistry at Stellenbosch University, South Africa, Director of Laboratory Research for the Desmond Tutu Tuberculosis Centre and former President of the South African Society of Biochemistry and Molecular Biology.

Each volume provides an essential resource to molecular and cell biologists, bacteriologists, immunologists, pathologists and pathophysiologists, clinicians and those working in the pharmaceutical industry and interested in world health.





For more information visit
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 20, 2008
Previous Article:Federal-Mogul's Fel-Pro(R) Performance Full Gasket Sets Include Premium, Race-Proven Technologies for Popular High-Output Engines.
Next Article:Delta Obtains ACE "Product Liability Insurance AAA Certification".

Related Articles
The war we thought we had won.
Transmission of Mycobacterium tuberculosis in a rural community, Arkansas, 1945-2000. (Tuberculosis Genotyping Network).
Get vaccinated.
In pixels and in health: computer modeling pushes the threshold of medical research.
Nosocomial tuberculosis in India.
Risk for tuberculosis among children.
Tuberculosis drug resistance and HIV infection, the Netherlands.
Disseminated bacillus Calmette-Guerin infection and immunodeficiency.
Cost-effectiveness of human papillomavirus vaccination in the United States.
Preventing and controlling emerging and reemerging transmissible diseases in the homeless.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters